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D
avid Davies stood at the hospital bedside of his great-
aunt, who had recently had all her toes amputated to 
try to prevent persistent wounds from spreading. It 
didn’t work; doctors would later amputate both of her feet, 
and she never returned to her independent life. As Davies 
thinks back to this episode from his high-school days, “I 
remember wondering ‘How come, in this era of antibiotics, 
was it not possible to treat what was obviously, to me, an 
infection?’”
Even today, such nonhealing wounds are common in 
people with late-stage diabetes like Davies’ great-aunt, who 
have poor circulation, as well as in people with compromised 
immune systems. Davies, now an associate professor at 
Binghamton University, says that many doctors treat these 
debilitating wounds as a problem with the patient, rather than 
a sign of infection. “There’s no excuse for it,” he says.
Wounds are just one example of the huge impact of 
bacterial bioﬁlms. The United States National Institutes 
of Health says that 80% of chronic infections are bioﬁlm 
related. Unlike the more familiar “planktonic” lifestyle, in 
which bacteria ﬂoat or swim freely, in bioﬁlms they surround 
themselves with a complex polymeric matrix, better known 
as “slime.” As it grows thicker, the ﬁlm often includes many 
bacterial species and the matrix develops a complex structure. 
Traditional antibiotics are often ineffective. “We thought we 
had it all ﬁgured out,” Davies says, but the past 20 years have 
shown that researchers are still in the “dark ages” when it 
comes to understanding and controlling bacteria.
As bioﬁlms, bacteria routinely foul industrial equipment 
and medical devices like catheters and implants, where they 
form dense layers that cling tightly to the artiﬁcial surfaces. 
They also occur naturally within us, most familiarly as dental 
plaque. In addition, bioﬁlms are increasingly blamed for 
recurrent and chronic infections. The case is clear for the 
Pseudomonas aeruginosa lung infections that haunt cystic 
ﬁbrosis patients and for recurrent middle ear infections of 
Haemophilus inﬂuenzae. But bioﬁlms are also prime suspects in 
a long list of other “itises,” including endocarditis, prostatitis, 
and conjunctivitis.
Researchers have learned much in recent years about the 
mechanisms that let bacteria establish a beachhead on a 
surface and work together to form a highly structured matrix 
that nourishes and protects them. The ﬁlms are easily seen 
by electron microscopy on foreign surfaces like catheters. 
However, deﬁnitively establishing a role for bioﬁlms in a 
particular disease—or in chronic wounds like those of Davies’ 
great-aunt—is difﬁcult, in part because traditional culture 
and assay techniques work best for planktonic forms. Even as 
the evidence comes in, however, many researchers are actively 
seeking unique vulnerabilities of the bioﬁlm state, hoping to 
control these stubborn ﬁlms wherever they occur.
A Stubborn Foe
The usual defenses often fail against bacteria that have 
formed bioﬁlms. The slimy matrix protects bacteria from 
assaults such as those by immune cells. In addition, bacteria 
in a bioﬁlm are 10–1,000 times more resistant to antibiotics 
than in their planktonic form.
“There’s no simple explanation why bioﬁlms are more 
resistant to antibiotics,” says George O’Toole of Dartmouth. 
He suggests that resistance is a natural part of adaptation 
to life on a surface. Although people like to think that we 
invented antibiotics to disrupt microbial processes, most were 
adapted from naturally occurring chemicals that the bacteria 
have evolved to resist. “Almost every antibiotic that’s out there 
is derived from another microbe,” O’Toole says. “Bacteria 
and fungi have been dealing with this biological warfare for 
millions or billions of years.”
At ﬁrst, researchers attributed the resistance mainly to 
the complex slime that the bacteria secrete. The slime does 
present a barrier to immune cells like phagocytes. However, 
experiments show that many antibiotics, as well as nutrients 
and waste products, readily diffuse through the water-rich 
matrix.
The slow metabolism of bioﬁlm cells also contributes 
to their resistance. The bacteria in the ﬁlm are relatively 
quiescent and divide only rarely. Antibiotics such as the 
penicillins, which need to be incorporated in the cell wall, are 
only effective against actively dividing cells. However, other 
antibiotics work just as well against quiescent cells, because 
they target basic cellular processes such as metabolism or 
protein or DNA synthesis. For reasons that are still being 
clariﬁed, even these antibiotics are less effective against 
bioﬁlms.
O, Pioneers!
Because bioﬁlms, once formed, are so hard to eradicate, 
many researchers—and makers of medical devices—have 
tried to stop them from forming in the ﬁrst place. A bioﬁlm 
starts when a few pioneer cells use specialized chemical hooks 
to adhere to a surface. These pioneers help to make a target 
surface more attractive to subsequent cells, which eventually 
mature into a complex, structured ﬁlm (Figure 1).
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Makers of medical devices, such as catheters, frequently try 
to prepare the device surfaces to disrupt the initial adhesion. 
For example, they may alter the physical characteristics or 
chemical properties of the surface, such as its hydrophobicity, 
to make it harder for these ﬁrst pioneers to stick. “Overall, 
these approaches haven’t been very successful,” asserts Phil 
Stewart. Stewart heads the Center for Bioﬁlm Research at 
Montana State University in Bozeman. One reason for this 
lack of success is that surfaces immersed in bodily ﬂuids 
develop a coating of bio-friendly material. Once the original 
surface is even partially covered, bacteria have a place to stick.
Other Approaches
Some researchers are going beyond simple surface treatments 
to incorporate biologically active agents into the surfaces 
of medical devices. Some naturally occurring proteins, like 
lactoferrin, interfere with bacterial adhesion. In addition, 
surfaces impregnated with antibiotics can delay bioﬁlm 
growth, although this technique has the important downside 
of encouraging resistant bacteria. These surface treatments 
are directly useful only for human-made devices, but they also 
provide a testing ground for possible treatments for medical 
bioﬁlms.
Strength in Diversity
Researchers are also exploiting the unique biochemistry 
of bacteria in bioﬁlms, such as a lack of iron or oxygen. 
Once a bioﬁlm is established, however, it develops a 
complex structure in which different cells occupy distinct 
environments. This diversity, both physiological and genetic, 
is an important part of bioﬁlms’ stubbornness, say Pradeep 
Singh of the University of Washington. First, “the cells are 
experiencing different environmental conditions, so their 
physiology is by nature different. The guys on the outside 
have very different physiology from the guys on the inside, so 
if you have a treatment or a target or a drug that affects one, 
the other may not be affected.” Levels of acidity, oxygen, and 
iron, for example, vary widely through the ﬁlm.
As the cells grow in these varying environments, they 
diverge genetically as well. In one study of bioﬁlm growth, 
Singh says, “if we started with genetically identical population 
of cells, after ﬁve or ten days we’d ﬁnd that population had 
actually diversiﬁed and was more like an old-growth forest 
than an monoculture of cells.” Like the forest, Singh suggests, 
the diversity of the bioﬁlm could be a key element of its 
robust response to antibiotics and other assaults.
The diversity clearly lets bioﬁlms recover rapidly. 
Researchers speak of a small population of cells, called 
“persisters,” that for one reason or another survive an 
immune or antibiotic attack. Afterwards, says Bill Costerton of 
the University of Southern California, “if you are a persister, 
you wake up in a puree of the guts of your neighbors that 
contains every molecule you ever needed.” These well-fed 
survivors can rapidly reestablish the ﬁlm once the assault 
doi:10.1371/journal.pbio.0050307.g001
Figure 1. Bioﬁlm Maturation Is a Complex Developmental Process Involving Five Stages
Stage 1, initial attachment; stage 2, irreversible attachment; stage 3, maturation I; stage 4, maturation II; stage 5, dispersion. Each stage of development 
in the diagram is paired with a photomicrograph of a developing P. aeruginosa bioﬁlm. All photomicrographs are shown to same scale.
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is over, he says. “Bioﬁlms have a regrowth rate that is truly 
phenomenal.”
Dealing effectively with this diversity may require a shift 
from the traditional single-antibiotic approach to bacteria. 
“If you look at a lot of other treatment regimens for other 
diseases—cancer, HIV—it’s almost always a cocktail of drugs 
targeting different aspects of the disease process,” says 
Dartmouth’s O’Toole. Combining antibiotics with other 
compounds that disrupt the formation or survival of the ﬁlm 
might render the bacteria more susceptible to antibiotics—
and could reduce antibiotic resistance, as well.
Majority Vote
As bacteria arrange into a bioﬁlm, the expression of scores 
of genes increases or decreases compared to their level in 
the planktonic form, raising hopes for targeting the bioﬁlm-
related pathways. Although many of the changes are still not 
understood, those involved in interbacterial signaling are 
especially promising. Indeed, for several species, researchers 
have identiﬁed signaling chemicals that perform in “quorum 
sensing,” which induces an abrupt change in phenotype 
when the density of nearby cells (and thus the signaling 
concentration) exceed a threshold level.
At ﬁrst, quorum sensing seemed to be a critical pathway 
for forming bioﬁlms, although the precise pathways differ 
somewhat between species. Recent results, however, show that 
mutant bacteria that can’t do quorum sensing can sometimes 
form bioﬁlms nonetheless. “The whole quorum sensing thing 
is still kind of shaking out,” says Montana State’s Stewart. 
Although he suspects that disrupting quorum sensing will 
remain an important tool, Stewart says, “my read at this point 
is it’s not as simple as ‘they have to be able to communicate to 
build a bioﬁlm.’”
In addition, Washington’s Singh says that the bacteria 
from the lungs of cystic ﬁbrosis patients who have long-
standing bioﬁlm infections are often mutants that can no 
longer perform quorum sensing. He suspects that once a 
bioﬁlm is established, the chemical signals could serve as a 
beacon for the immune system. In their ongoing battle to 
evade detection, the bacteria may evolve to suppress quorum 
sensing when it is not helpful.
Not Just a Pretty Phage
Once bioﬁlms develop, their most obvious distinguishing 
feature is the slime they secrete, which both holds the cells 
together and helps protect them (Figure 2). This richly 
structured matrix consist of a goulash of polysaccharides, as 
well as lipids, proteins, and even nucleic acids. Chemicals that 
attack this slime chemically can disrupt a variety of bioﬁlms 
on medical equipment. Such a general assault is tricky for 
internal infections, but can be effective when applied directly 
to wounds.
Another strategy exploits viruses called phages that 
target bacteria. Phages tend to be highly speciﬁc, targeting 
particular species and even strains of bacteria. This speciﬁcity 
can be useful, especially for systemic treatments, because 
it can avoid disrupting natural, beneﬁcial populations of 
bacteria, such as those in the gut. These beneﬁcial bacteria 
often occur in bioﬁlms themselves, and can naturally suppress 
more troublesome strains. 
However, doctors might need to know which speciﬁc 
organisms causing an infection in order to choose a phage 
to treat it. This may not be as difﬁcult as it seems, since a few 
organisms (such as P. aeruginosa, Escherichia coli, Staphylococcus 
aureus, and S. epidermidis) are responsible for a large fraction 
of infections. Researchers in the former Soviet Union 
have used phage to treat infections for decades and have 
developed cocktails that attack a spectrum of organisms. 
In this country, there are both practical and regulatory 
challenges to introducing active viruses into patients, but that 
may be changing.
“My sense is that increasingly the US community is open 
to the potential of using phage,” says Jim Collins of Boston 
University. With colleague Timothy Lu, Collins has used 
synthetic biology to alter natural viruses, adding genes for 
enzymes that attack the slime. The phage ﬁrst hijack the 
bacterial machinery to replicate themselves, then break the 
cells open to release not just the copies, but the enzyme. 
Compared to the phage alone, this engineered phage “was 
about 100 times more effective” at disrupting a laboratory 
bioﬁlm, Collins says.
Rodney Donlon heads a team at the US Centers for 
Disease Control and Prevention aiming to reduce infections 
in medical devices. He says that the engineered phage is 
“very interesting,” although the genetic engineering of the 
virus could raise further concerns about its release into the 
environment. Still, Donlon emphasizes that phage naturally 
only attack bacteria. “They will not infect human or plant 
cells.” But the phage are not without problems, such as 
the release of toxins when the cells split open or immune 
responses to the viruses like those that have dogged gene 
therapy trials.
Donlon has explored phage for devices, incorporating 
them into coatings on catheters. In what Donlon describes 
as a “proof of principle,” these coatings suppress the growth 
of bioﬁlms in laboratory tests. Interestingly, they appear to 
remain active even after exposure to bodily ﬂuids.
Harnessing Dispersion
Since each bioﬁlm is different, however, researchers may 
need to tailor their approach to a particular species and 
doi:10.1371/journal.pbio.0050307.g002
Figure 2. A S. aureus Bioﬁlm on the Surface of a Medical Catheter 
That Was Removed from a Patient
The round bacteria secrete a complex “slime” that helps protect them 
from attack by antibiotics and other antimicrobial agents. Electron 
micrograph magniﬁed 2363×.
(Image Credit: CDC/Rodney M. Donlan, Ph.D.; Janice Carr (PHIL #7488), 
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matrix—or a combination. To overcome this problem, 
Binghamton’s Davies looked at the ﬁnal stage of the life 
cycle of bioﬁlms: autodispersal. In this stage, regions of the 
ﬁlm spontaneously disperse as cells dissolve the matrix by 
secreting enzymes and revert to their planktonic form.
Davies’ team found a signaling molecule that initiates 
autodispersal. As in quorum sensing, this signal induces 
a profoundly different behavior above a threshold 
concentration. The chemical signals are completely different, 
however, and instead of causing ﬁlms to coalesce, it causes 
them to break up.
One of the most tantalizing aspects of this molecule is that it 
appears to be universal across bacterial species. Although the 
enzymes required to degrade the matrix differ between species, 
the same signaling molecule triggers the process. Davies’ team 
has identiﬁed the molecule and veriﬁed that a synthesized 
version induces dispersal even in ﬁlms that are below the 
threshold density, and works even in multispecies bioﬁlms.
For widespread infections like those in cystic ﬁbrosis, 
instantaneously releasing billions of bacteria in their 
planktonic form could cause even worse problems than the 
ﬁlm. But for localized infections, like those in the sinus or 
middle ear, Davies thinks his dispersion-inducer could make 
intractable infections vulnerable to traditional antibiotics, 
or even to normal immune response. “Most infections are 
very localized, and it’s not easy for the cells to really get very 
far from the site of the bioﬁlm infection,” he says. At a more 
personal level, Davies hopes that the dispersal agent could 
help millions of people with nonhealing wounds, like those of 
his aunt.
Dealing with Chronic Wounds
In fact, recent results show bioﬁlms in many chronic wounds, 
says Randall Wolcott, who heads the Southwest Regional 
Wound Care Center in Lubbock, Texas. “Six months from 
now, I think the wound-care community will fully accept 
bioﬁlm as a major barrier to healing.”
Although worried about being branded as “one of those 
alternative-medicine types,” Wolcott has been exploring anti-
bioﬁlm therapies. “I watched so many people die, in their 
forties and ﬁfties, a piece at a time,” he says. “I’d just had 
enough.” Overall, he says, “bioﬁlm disease kills more people 
than cancer.”
For wounds that don’t respond to standard-of-care wound 
treatment, including mechanical removal of damaged tissue, 
Wolcott adds as many as six or seven agents to kill bacteria 
and disrupt the bioﬁlms. He also uses phages, which qualify 
as natural substances and has occasionally seen “wounds that 
have been present for years go on to heal up in weeks.”
These ongoing studies show the potential for treatments 
directed at bioﬁlms, especially in combinations that counter 
the natural diversity of the bioﬁlm populations. “We know 
how to manage bioﬁlms,” says Wolcott. “We just need to bring 
it into medicine.”  
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